Accelerate Diagnostics, INC 8-K filings
Current reports — the filing a company makes when something happens that shareholders need to know about before the next quarterly report.
Accelerate Diagnostics, Inc. has consummated the sale of certain assets to Indaba Capital Management and confirmed its Chapter 11 liquidation plan, resulting in the cancellation of all outstanding common stock and warrants with no recovery for equity holders.
Accelerate Diagnostics, Inc. has entered into a definitive agreement to sell substantially all of its assets to Indaba Starling, LLC, an affiliate of its secured noteholder, as part of its ongoing Chapter 11 bankruptcy proceedings, with common stockholders expected to face significant or complete loss.
Accelerate Diagnostics, Inc. announced that Chief Financial Officer David Patience will resign effective June 30, 2025, to pursue other professional opportunities.
Accelerate Diagnostics, Inc. is set to be delisted from the Nasdaq Stock Market due to its recent Chapter 11 bankruptcy filing and failure to meet minimum bid price and market value requirements.
Accelerate Diagnostics has voluntarily initiated Chapter 11 proceedings and agreed to terms with Indaba Capital Management for the sale of substantially all of its assets.
Accelerate Diagnostics, Inc. has entered into a retention bonus agreement with its President and CEO, Jack Phillips, providing him with a $200,000 bonus.
Accelerate Diagnostics adds two independent directors, Paul Shalhoub and Gilbert Nathan, and forms a special committee to explore strategic options aimed at maximizing value.
Accelerate Diagnostics has submitted its WAVE system and positive blood culture gram-negative test kit to the FDA for 510(k) clearance, aiming to provide rapid antimicrobial susceptibility testing.
Accelerate Diagnostics, Inc. reports a decrease in net sales for both the fourth quarter and full year 2024, alongside a reduction in operating expenses and a net loss.
Accelerate Diagnostics received a notice from Nasdaq regarding non-compliance with the minimum Market Value of Listed Securities requirement, placing the company at risk of delisting.
Accelerate Diagnostics reports preliminary 2024 results, highlighting progress with its WAVE system clinical trial and a reduction in cash burn.
Accelerate Diagnostics announced its Q3 2024 financial results, highlighting FDA clearance for its Accelerate Arc system and the start of clinical trials for its WAVE system, while experiencing a slight dip in net sales.
Accelerate Diagnostics has announced that the FDA has granted 510(k) clearance for its Accelerate Arc system and BC kit, an automated platform for rapid microbial identification.
Accelerate Diagnostics has received notification from Nasdaq that it has regained compliance with the minimum Market Value of Listed Securities requirement.
Accelerate Diagnostics has entered into a note purchase agreement for $15 million in super-priority senior secured notes due in 2025.
Accelerate Diagnostics reported its second quarter 2024 financial results, highlighted by a successful pre-clinical trial for its WAVE system and a $15 million capital raise.
Accelerate Diagnostics has regained compliance with Nasdaq's minimum bid price requirement after its stock price closed above $1.00 for ten consecutive business days.
Accelerate Diagnostics has dismissed Ernst & Young as its auditor and appointed Withum Smith+Brown, effective June 1, 2024.
Accelerate Diagnostics has granted long-term and performance-based incentive awards to its top executives, contingent on achieving FDA approval for the Accelerate Wave system by specific deadlines.
Accelerate Diagnostics closed the second tranche of its private placement with the Jack W. Schuler Living Trust, raising approximately $2.7 million.
Accelerate Diagnostics' shareholders approved a 4 million share increase to the company's equity incentive plan and re-elected all nine board members at the 2024 annual meeting.
Accelerate Diagnostics has updated its Q1 2024 financial results, primarily due to non-cash accounting revisions related to a January 2024 equity financing, resulting in a reduced net loss.
Accelerate Diagnostics announced preliminary first quarter 2024 financial results, noting progress with their Accelerate Wave system and securing long-term customer contracts.
Accelerate Diagnostics has received a notice from Nasdaq regarding its failure to maintain the minimum $1.00 per share bid price, placing it at risk of delisting.
Accelerate Diagnostics announced its fourth quarter and full-year 2023 financial results, highlighting progress in its next-generation rapid antibiotic susceptibility testing system, Accelerate Wave, while facing revenue and margin challenges.
Accelerate Diagnostics has received a notice from Nasdaq for failing to maintain the minimum market value of listed securities, putting its listing status at risk.
Accelerate Diagnostics closed a public offering of units and secured approximately $4.75 million through private placements with management and a major shareholder.